Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|April 15, 2008
New report warns of link between insurance fraud and drug diversion
The Coalition Against Insurance Fraud has issued a report about the harmful effects of insurance fraud and what actions can be taken to prevent it from occurring.
Advertisement
Advertisement
Related to this article
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
3
Expert Discusses Flu and COVID-19 Vaccine Guidance
4
Nicotine Pouches Create Opportunity for Pharmacist Counseling
5